Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 7/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12197818 | 0.83 | CYP19A1 (0.36) | CYP19A1HTR2CHTR2AHTR2BMAOB | |
| SCHEMBL18218827 | 0.74 | HTR2A (0.52) | HTR2CHTR2AHTR2BGRIA2PDE4A | |
| SCHEMBL24662942 | 0.73 | MAOA (0.42) | CYP19A1HTR2CMAOB | |
| SCHEMBL9174102 | 0.72 | CYP19A1 (0.39) | CYP19A1HTR2CMAOBNPC1TERT | |
| SCHEMBL8575685 | 0.72 | CYP19A1 (0.39) | CYP19A1HTR2CMAOBNPC1TERT | |
| SCHEMBL3227142 | 0.72 | GRIA1 (0.60) | CYP19A1HTR2CHTR2AHTR2BMAOB | |
| SCHEMBL4070655 | 0.72 | ALDH1A1 (0.37) | PKM | |
| SCHEMBL13595240 | 0.71 | HTR2C (0.65) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL4419505 | 0.70 | HTR2C (0.64) | HTR2CHTR2AHTR2B | |
| SCHEMBL20786546 | 0.70 | NPC1 (0.43) | CYP19A1HTR2CMAOBNPC1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173644-B2 | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses | LES LABORATOIRES SERVIER (FR) | 2012-05-08 | — | — | US | disclosed |
| US-8173644-B2 | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses | LES LABORATOIRES SERVIER (FR) | 2012-05-08 | — | — | US | disclosed |
| US-20100137295-A1 | 3-SUBSTITUTED-[1,2,3]-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | LES LABORATOIRES SERVIER (FR) | 2010-06-03 | — | — | US | disclosed |
| US-20100137295-A1 | 3-SUBSTITUTED-[1,2,3]-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | LES LABORATOIRES SERVIER (FR) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137295-A1 | 3-SUBSTITUTED-[1,2,3]-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN1, GRIN3B, GRIN3A | CYP19A1 4083/4885HTR2C 180/4885HTR2A 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.